Resent Acquisitions in this Sector
Recent acquisitions indicate a strong market interest and an opportunity for substantial returns on investment.
BD Acquired Edwards' Critical Care for $4.2 Billion
June 2024 press release
Sept 2024 press release
About Edwards' Critical Care:
Core product: The gold-standard Swan-Ganz pulmonary artery catheters for monitoring Critical Care and HF patients
$928M total sales in 2023
7% yearly sales growth
About BD (NYSE: BDX):
One of the largest global medical technology companies in the world
$19.4B revenue in 2023
Edwards Acquired Endotronix for $675 Million
July 2024 press release
About Endotronix:
Product: Permanent electronic cardiac implant for monitoring chronic HF patients
$130M raised across 10 funding rounds from 12 investors, including strategic corporate partners Edwards and Medtronic
ROI 5.2x following FDA clearance in June 2024
Edwards Acquired JenaValve for $945 Million
July 2024 press release
About JenaValve:
Product: Specialized TAVR valve for patients with severe aortic regurgitation
$342M raised across 11 funding rounds from 21 investors
ROI 2.8x prior FDA clearance and without strategic corporate partner
Johnson & Johnson Acquired V-Wave for $1.7 Billion
August 2024 press release
About V-Wave:
Product: Interatrial shunt cardiac implant for chronic HF patients
$226M raised across 5 funding rounds from 13 investors, including strategic corporate partner Johnson & Johnson
ROI 7.5x following FDA clearance